CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.
June 7th 2023
Meaningful improvements in survival were obtained with Zejula maintenance therapy compared with placebo in patients with advanced ovarian cancer that was newly diagnosed.
June 3rd 2023
A progression-free survival benefit was observed in patients with advanced ovarian cancer including those with homologous recombination deficient-positive status who were treated with frontline chemo plus Avastin and Imfinzi followed by maintenance therapy with an Avastin regimen.
May 8th 2023
As more personalized treatments become available in the ovarian cancer space, tumor testing, such as next-generation sequencing, may play a bigger role.
May 4th 2023
Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.
April 24th 2023
The best part of the trip was that I didn’t think about cancer. My husband and I didn’t talk about it for a whole week, and no one knew I had it.
April 20th 2023
Before being diagnosed with stage 3 ovarian cancer at the age of 34, Jennifer Broxterman was constantly told that she was young and healthy — but the registered dietitian knew that something was off.
April 10th 2023
A pharmaceutical company initiated a phase 1b study in patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
April 7th 2023
There are certain side effects from Elahere — a newly approved ovarian cancer drug — that patients taking the treatment should look out for, an expert said.
April 6th 2023
Social media, including Facebook groups, can help connect patients with rare cancers like granulosa cell tumors to researchers, allowing them to learn more about disease management.
April 6th 2023
Interim findings from a clinical trial showed that adding Lynparza and Imfinzi to an Avastin and chemotherapy regimen tended to improve the time patients lived before their disease got worse.
March 28th 2023
Twenty-five years ago, I was diagnosed with ovarian cancer, which sparked fears of leaving my loved ones behind.
March 27th 2023
Patients with ovarian cancer who utilized palliative care tended to have fewer hospital readmissions than those who did not, according to a recent study.
March 27th 2023
The temporary tattoos that guided the radiation for my cancer treatment were not beautiful, artistic or cool — they were more than that.
March 13th 2023
Positive results have emerged from a trial testing PIPAC, a procedure used for appendiceal, ovarian, gastric and colon cancers that works by spraying chemotherapy directly onto tumors.
February 10th 2023
After promising phase 1 results, ART0380 will be studied in a randomized phase 2 trial for patients with platinum-resistant ovarian cancer.
February 1st 2023
I’m coming up on my 10-year cancer anniversary, and it feels bittersweet.
January 30th 2023
Women with low-grade serous ovarian cancer treated with avutometinib and defactinib experienced positive response rates compared with avutometinib alone.
January 19th 2023
The trial is evaluating the safety and efficacy of AVB-001 patients with relapsed refractory ovarian cancer.
January 18th 2023
Women who were taking beta-blockers, a medicine to treat heart conditions like high blood pressure, among others, near the time of surgery for epithelial ovarian cancer may confer a survival benefit years after undergoing a procedure.
November 22nd 2022
One expert said that the FDA approval of the antibody-drug conjugate Elahere represents a new treatment option for patients with folate receptor alpha-positive, platinum resistant ovarian cancer.
October 28th 2022
Researchers running clinical should be aware of how these new drugs affect our day-to-day lives — not just in the big ways, but also the small ones that take their toll over the long haul.
October 27th 2022
Women who face menopause after a cancer diagnosis may be able to manage their symptoms without relying on estrogen-based therapies, although discussing this with a cancer team will help patients find what’s best for them.
October 7th 2022
From the death of standup comedian and "Love Goddess" Judy Tenuta to professional sports hall-of-famers discussing their cancer, here’s what’s happening in the cancer space this week.
September 27th 2022
The novel drug PY159 will be studied as a single agent and in combination with Keytruda for patients with certain solid tumors — including ovarian, pancreatic, lung, head and neck, colorectal and breast cancers.
September 26th 2022
The OnPrime trial will investigate if adding Olvi-Vec, a modified virus, to chemotherapy and Avastin will improve outcomes for pretreated platinum-resistant or refractory ovarian cancer.
September 15th 2022
Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.
September 11th 2022
BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.
September 9th 2022
Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.
September 8th 2022
The first patient was treated in a phase 2 trial assessing the safety and efficacy of navicixizumab, with or without chemotherapy, in colorectal, gastric, ovarian and breast cancer.